Emergent Biosolutions (EBS) Price Target Increased to $53.00 by Analysts at Chardan Capital

Emergent Biosolutions (NYSE:EBS) had its price objective raised by Chardan Capital from $47.00 to $53.00 in a report issued on Tuesday morning. Chardan Capital currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently commented on the stock. Zacks Investment Research cut shares of Emergent Biosolutions from a strong-buy rating to a hold rating in a research note on Tuesday, December 19th. Wells Fargo & Co reissued an outperform rating and issued a $43.00 price objective (up from $41.00) on shares of Emergent Biosolutions in a research note on Saturday, September 30th.

Shares of Emergent Biosolutions (EBS) traded up $1.01 on Tuesday, hitting $49.83. 350,798 shares of the stock were exchanged, compared to its average volume of 339,291. The company has a debt-to-equity ratio of 0.38, a current ratio of 7.37 and a quick ratio of 6.46. The stock has a market cap of $1,967.94, a P/E ratio of 29.49, a PEG ratio of 0.99 and a beta of 1.25. Emergent Biosolutions has a 1-year low of $27.94 and a 1-year high of $50.14.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.32. The business had revenue of $149.43 million during the quarter, compared to the consensus estimate of $124.55 million. Emergent Biosolutions had a net margin of 15.60% and a return on equity of 15.20%. The business’s revenue was up 4.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.56 EPS. equities analysts forecast that Emergent Biosolutions will post 1.66 EPS for the current fiscal year.

In related news, Director Zsolt Harsanyi sold 7,000 shares of the stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $42.47, for a total value of $297,290.00. Following the sale, the director now directly owns 37,077 shares of the company’s stock, valued at approximately $1,574,660.19. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Daniel Abdun-Nabi sold 21,906 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $47.91, for a total transaction of $1,049,516.46. Following the completion of the sale, the chief executive officer now directly owns 226,040 shares in the company, valued at $10,829,576.40. The disclosure for this sale can be found here. Over the last three months, insiders sold 206,329 shares of company stock worth $8,892,362. 16.50% of the stock is owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP boosted its stake in shares of Emergent Biosolutions by 0.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,224,198 shares of the biopharmaceutical company’s stock worth $89,968,000 after purchasing an additional 18,486 shares during the last quarter. Royal Bank of Canada boosted its stake in shares of Emergent Biosolutions by 2.1% during the 2nd quarter. Royal Bank of Canada now owns 958,568 shares of the biopharmaceutical company’s stock worth $32,505,000 after purchasing an additional 19,833 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Emergent Biosolutions by 47.2% during the 2nd quarter. Northern Trust Corp now owns 906,731 shares of the biopharmaceutical company’s stock worth $30,747,000 after purchasing an additional 290,863 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Emergent Biosolutions by 16.7% during the 2nd quarter. Renaissance Technologies LLC now owns 820,411 shares of the biopharmaceutical company’s stock worth $27,820,000 after purchasing an additional 117,700 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Emergent Biosolutions by 2.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 631,304 shares of the biopharmaceutical company’s stock worth $21,409,000 after purchasing an additional 15,314 shares during the last quarter. 88.44% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was posted by Week Herald and is the sole property of of Week Herald. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://weekherald.com/2018/01/17/emergent-biosolutions-ebs-price-target-increased-to-53-00-by-analysts-at-chardan-capital.html.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply